Skip to main content
SpringerLink
Log in
Book cover

Cancer Prevention pp 19–36Cite as

Genetic Risk Profiles for Cancer Susceptibility and Therapy Response

  • Conference paper

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 174))

Abstract

Cells in the body are permanently attacked by DNA-reactive species, both from intracellular and environmental sources. Inherited and acquired deficiencies in host defense mechanisms against DNA damage (metabolic and DNA repair enzymes) can modify cancer susceptibility as well as therapy response. Genetic profiles should help to identify high-risk individuals who subsequently can be enrolled in preventive measures or treated by tailored therapy regimens. Some of our attempts to define such risk profiles are presented. Cancer susceptibility: Single nucleotide polymorphisms (SNPs) in metabolic and repair genes were investigated in a hospital-based lung cancer case—control study. When evaluating the risk associated with different genotypes for N-acetyltransferases (Wikman et al. 2001) and glutathione-S-transferases (Risch et al. 2001), it is mandatory to distinguish between the three major histological subtypes of lung tumors. A promoter polymorphism of the myeloperoxidase gene MPO was shown to decrease lung cancer susceptibility mainly in small cell lung cancer (SCLC) (Dally et al. 2002). The CYP3A4*1B allele was also linked to an increased SCLC risk and in smoking women increased the risk of lung cancer eightfold (Dally et al. 2003b). Polymorphisms in DNA repair genes were shown to modulate lung cancer risk in smokers, and reduced DNA repair capacity elevated the disease risk (Rajaee-Behbahani et al. 2001). Investigations of several DNA repair gene variants revealed that lung cancer risk was only moderately affected by a single variant but was enhanced up to approximately threefold by specific risk allele combinations (Popanda et al. 2004). Therapy response: Interindividual differences in therapy response are consistently observed with cancer chemotherapeutic agents. Initial results from ongoing studies showed that certain polymorphisms in drug transporter genes (ABCB1) differentially affect response outcome in histological subgroups of lung cancer. Stronger beneficial effects were seen in non-small cell lung cancer (NSCLC) patients following gemcitabine and in SCLC patients following etoposide-based treatment. Several DNA repair parameters (polymorphisms, RNA expression, and DNA repair capacity) were measured in vitro in lymphocytes of patients before radiotherapy and correlated with the occurrence of acute side effects (radio-hypersensitivity). Our initial analysis of several repair gene variants in breast cancer patients (n=446) who received radiotherapy revealed no association of single polymorphisms and the development of side effects (moist desquamation of the irradiated normal skin). The risk for this side effect was, however, strongly reduced in normal weight women carrying a combination of XRCC1 399Gln and APE1 148Glu alleles, indicating that these variants afford some protection against radio-hypersensitivity (Chang-Claude et al. 2005). Based on these data we conclude that specific metabolic and DNA repair gene variants can affect cancer risk and therapy outcome. Predisposition to hereditary cancer syndromes is dominated by the strong effects of some high-penetrance tumor susceptibility genes, while predisposition to sporadic cancer is influenced by the combination of multiple low-penetrance genes, of which as a major challenge, many disease-relevant combinations remain to be identified. Before translating these findings into clinical use and application for public health measures, large populationbased studies and validation of the results will be required.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alberola V, Sarries C, Rosell R, Taron M, de las Peñas R, Camps C, Massuti B, Insa A, Garcia-Gomez R, Isla D, Artal A, Muñoz MA, Cobo M, Bover I, Gonzalez-Larriba JL, Terrasa J, Almenar D, Barcelo R, Diz P, Sanchez-Ronco M, Sanchez JJ (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin Lung Cancer 5:360–365

    Article  PubMed  CAS  Google Scholar 

  • Andreassen CN, Alsner J, Overgaard J (2002) Does variability in normal tissue reactions after radiotherapy have a genetic basis — where and how to look for it? Radiother Oncol 64:131–140

    Article  PubMed  Google Scholar 

  • Bartsch H, Hietanen E (1996) The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 104:569–577

    Article  PubMed  CAS  Google Scholar 

  • Berwick M, Vineis P (2000) Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92:874–897

    Article  PubMed  CAS  Google Scholar 

  • Berwick M, Vineis P (2005) Measuring DNA repair capacity: small steps. J Natl Cancer Inst 97:84–85

    PubMed  Google Scholar 

  • Brambilla E, Brambilla C, Lanhiejoul S (2005) Impact of molecular pathology on the clinical management of lung cancer. Respiration 72:229–232

    Article  PubMed  Google Scholar 

  • Bürkle A (2001) Poly(APD-ribosyl)ation, a DNA damage-driven protein modification and regulator of genomic instability. Cancer Lett 163:1–5

    Article  PubMed  Google Scholar 

  • Bürkle A (2005) Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J 272:4576–4589

    Article  PubMed  CAS  Google Scholar 

  • Burnet NG, Johansen J, Turesson I, Nyman J, Peacock JH (1998) Describing patients’ normal tissue reactions: concerning the possibility of individualizing radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Int J Cancer 79:606–613

    Article  PubMed  CAS  Google Scholar 

  • Butkiewicz D, Popanda O, Risch A, Edler L, Dienemann H, Schulz V, Kayser K, Drings P, Bartsch H, Schmezer P (2004) Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene. Cancer Epidemiol Biomarkers Prev 13:2242–2246

    PubMed  CAS  Google Scholar 

  • Candelaria M, Taja-Chayeb L, Arce-Salinas C, Vidal-Millan S, Serrano-Olvera A, Duenas-Gonzalez A (2005) Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. Anticancer Drugs 16:923–933

    Article  PubMed  CAS  Google Scholar 

  • Chang-Claude J, Popanda O, Tan X-L, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Ambrosone CB (2005) Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11:4802–4809

    Article  PubMed  CAS  Google Scholar 

  • Dally H, Gassner K, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K, Bartsch H, Risch A (2002) Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO-463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 102:530–535

    Article  PubMed  CAS  Google Scholar 

  • Dally H, Bartsch H, Risch A (2003a). Correspondence re: Feyler et al., Point: myeloperoxidase (-463)G → A polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 11:1550–1554, 2002, and Xu et al., Counterpoint: The myeloperoxidase (463)G → A polymorphism does not decrease lung cancer susceptibility in Caucasians. 11: I555–1559, 2002. Cancer Epidemiol Biomarkers Prev 12:683

    Google Scholar 

  • Dally H, Edler L, Jäger B, Schmezer P, Spiegelhalder B, Drings P, Dienemann H, Schulz V, Kayser K, Bartsch H, Risch A (2003b) The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13:607–618

    Article  PubMed  CAS  Google Scholar 

  • Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML (2000) Gender differences in genetic susceptibility for lung cancer. Lung Cancer 30:153–160

    Article  PubMed  CAS  Google Scholar 

  • Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107:155–176

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119–137

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464–468

    Article  PubMed  CAS  Google Scholar 

  • Fijneman RJA (2005) Genetic predisposition to sporadic cancer: how to handle major effects of minor genes? Cellular Oncology 27:281–292

    PubMed  CAS  Google Scholar 

  • Fischer JR, Lahm H (2004) Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer 45:S5151–S1617

    Article  Google Scholar 

  • Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Daniel Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC (2006) Cyclin Dl (CCND1) A870G gene polymorphism modulates smokinginduced lung cancer risk and response to platinumbased chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 51:303–311

    Article  PubMed  Google Scholar 

  • Grattendick K, Stuart R, Roberts E, Lincoln J, Lefkowitz SS, Bollen A, Moguilevsky N, Friedman H, Lefkowitz DL (2002) Alveolar macrophage activation by myeloperoxidase: a model for exacerbation of lung inflammation. Am J Respir Cell Mol Biol 26:716–722

    PubMed  CAS  Google Scholar 

  • Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374

    Article  PubMed  CAS  Google Scholar 

  • Hu JJ, Roush GC, Dubin N, Berwick M, Roses DF, Harris MN (1997) Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis. Pharmacogenetics 7:309–316

    Article  PubMed  CAS  Google Scholar 

  • Huang Z, Guengerich FP, Kaminsky LS (1998) 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 19:867–872

    Article  PubMed  CAS  Google Scholar 

  • Hümmerich J, Werle-Schneider G, Popanda O, Celebi O, Chang-Claude J, Kropp S, Mayer C, Debus J, Bartsch H, Schmezer P (2006) Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radiosensitivity: a pilot study in prostate cancer patients receiving radiotherapy Int J Radiat Biol 82:593–604

    Article  PubMed  CAS  Google Scholar 

  • Iwakawa M, Goto M, Noda S, Sagara M, Yamada S, Yamamoto N, Kawakami Y, Matsui Y, Miyazawa Y, Yamazaki H, Tsuji H, Ohno T (2005) DNA repair capacity measured by high throughput alkaline comet assays in EBV-transformed cell lines and peripheral blood cells from cancer patients and healthy volunteers. Mutat Res 588:1–6

    PubMed  CAS  Google Scholar 

  • Jassem J (1999) Chemotherapy of advanced non-small cell lung cancer. Ann Oncol 10[Suppl 6]:77–82

    Article  PubMed  Google Scholar 

  • Kayser K (1992) Analytical lung pathology. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Larsen JE, Colosimo ML, Yang LA, Bowman R, Zimmerman PV, Fong KM (2006) CYP1A1 I1e462Va1 and MPO G-46 3A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis 27:525–532

    Article  PubMed  CAS  Google Scholar 

  • Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111

    Article  PubMed  CAS  Google Scholar 

  • Lipshutz R (2005) Using microarrays to detect disease and tailor therapy. Pharmaceut Discov 5:28–37

    CAS  Google Scholar 

  • Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, Hu JJ (2004) The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 64:6344–6348

    Article  PubMed  CAS  Google Scholar 

  • Matullo G, Peluso M, Polidoro S, Guarrera S, Munnia S, Krogh V, Masala G, Berrino F, Panico S, Tumino R, Vineis P, Palli D (2003) Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a populationbased study. Cancer Epidemiol Biomarkers Prev 12:674–677

    PubMed  CAS  Google Scholar 

  • Matsuzaki H, Dong S, Loi H, Di X, Liu G, Hubbell E, Law J, Berntsen T, Chadha H, Hui H, Yang G, Kennedy GC, Webster TA, Cawley S, Walsh PS, Jones KW, Fodor SP, Mei R (2004) Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat Methods 1:109–111

    Article  PubMed  CAS  Google Scholar 

  • Mayer C, Popanda O, Zelezny O, von Brevern M-C, Bach A, Bartsch H, Schmezer P (2002) DNA repair capacity after gamma-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes. DNA Repair (Amst) 1:237–250

    Article  CAS  Google Scholar 

  • Mayne ST, Buenconsejo J, Janerich DT (1999) Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 149:13–20

    PubMed  CAS  Google Scholar 

  • Mohrenweiser HW, Wilson DM III, Jones IM (2003) Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 526:93–125

    PubMed  CAS  Google Scholar 

  • Muscat JE, Wynder EL (1995) Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett 88:1–5

    Article  PubMed  CAS  Google Scholar 

  • Nebert DW, Vesell ES (2004) Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 500:267–280

    Article  PubMed  CAS  Google Scholar 

  • Pauk N, Kubik A, Zatloukal P, Krepela E (2005) Lung cancer in women. Lung Cancer 18:1–9

    Article  Google Scholar 

  • Peters L, McKay M (2001) Predictive assays: will they ever have a role in the clinic? Int J Radiat Oncol Biol Phys 49:501–504

    Article  PubMed  CAS  Google Scholar 

  • Popanda O, Ebbeler R, Twardella D, Helmbold I, Gotzes F, Schmezer P, Thielmann HW, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Bartsch H, Chang-Claude J (2003) Radiation-induced DNA damage and repair in lymphocytes from breast cancer patients and their correlation with acute skin reactions to radiotherapy. Int J Radiat Oncol Biol Phys 55:1216–1225

    Article  PubMed  Google Scholar 

  • Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, Edler L, Kayser K, Dienemann H, Schulz V, Drings P, Bartsch H, Schmezer P (2004) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 25:2433–2441

    Article  PubMed  CAS  Google Scholar 

  • Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, Schulz V, Drings P, Thiel S, Bartsch H (2001) Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer 95:86–91

    Article  PubMed  CAS  Google Scholar 

  • Rajaee-Behbahani N, Schmezer P, Ramroth H, Bürkle A, Bartsch H, Dietz A, Becher H (2002) Reduced poly(ADP-ribosyl)ation in lymphocytes of laryngeal cancer patients: results of a case-control study. Int J Cancer 98:780–784

    Article  PubMed  CAS  Google Scholar 

  • Raunio H, Hakkola J, Pelkonen O (2005) Regulation of CYP3A genes in the human respiratory tract. Chem Biol Interact 151:53–62

    Article  PubMed  CAS  Google Scholar 

  • Relling MV, Dervieux T (2001) Pharmacogenetics and cancer therapy. Nat Rev Cancer 1:99–108

    Article  PubMed  CAS  Google Scholar 

  • Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817–2823

    PubMed  CAS  Google Scholar 

  • Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB (1993) Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 138:281–293

    PubMed  CAS  Google Scholar 

  • Risch A, Wikman H, Thiel S, Schmezer P, Edler L, Drings P, Dienemann H, Kayser K, Schulz V, Spiegelhalder B, Bartsch H (2001) Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics 11:757–764

    Article  PubMed  CAS  Google Scholar 

  • Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, Margel M, Felip E, Mendez P, Garcia-Campelo R (2004) Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31:20–27

    Article  PubMed  CAS  Google Scholar 

  • Schmezer P, Rajaee-Behbahani N, Risch A, Thiel S, Rittgen W, Drings P, Dienemann H, Kayser KW, Schulz V, Bartsch H (2001) Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis 16:25–30

    Article  PubMed  CAS  Google Scholar 

  • Schunck C, Johannes T, Varga D, Lorch T, Plesch A (2004) New developments in automated cytogenetic imaging: unattended scoring of dicentric chromosomes, micronuclei, single cell gel electrophoresis, and fluorescence signals. Cytogenet Genome Res 104:383–389

    Article  PubMed  CAS  Google Scholar 

  • Scripture CD, Sparreboom A, Figg WD (2005) Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6:780–789

    Article  PubMed  CAS  Google Scholar 

  • Spitz MR, Wei Q, Dong Q, Amos CI, Wu X (2003) Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 12:689–698

    PubMed  CAS  Google Scholar 

  • Spitz MR, Wu X, Mills G (2005) Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23:267–275

    Article  PubMed  Google Scholar 

  • Tan XL, Popanda O, Ambrosone CB, Kropp S, Helmbold I, von Foumier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J (2005) Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 97:255–262

    Article  PubMed  CAS  Google Scholar 

  • Thomas M, Baumann M, Deppermann M, Freitag L, Gatzemeier U, Huber R, Passlick B, Serke M, Ukena D (2002) Recommendations on the therapy of bronchial carcinoma. Pneumologie 56:113–131

    Article  PubMed  CAS  Google Scholar 

  • Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF, Shimizu N (2006) Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66:1371–1375

    Article  PubMed  CAS  Google Scholar 

  • Twardella D, Popanda O, Helmbold I, Ebbeler R, Benner A, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J (2003) Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. Radiother Oncol 69:145–153

    Article  PubMed  CAS  Google Scholar 

  • US NIH Cancer Therapy Evaluation Program (1999) Common Toxicity Criteria; Available from: http://ctep.cancer.gov/reporting/ctc.html. Cited 4 August 2006

    Google Scholar 

  • Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic L, Martinez E, Illarramendi JJ, Arias F, Martinez MR, Salgado E, Angeletti S, Brugarolas A (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779–1786

    PubMed  CAS  Google Scholar 

  • Vineis P (2004) Individual susceptibility to carcinogens. Oncogene 23:6477–6483

    Article  PubMed  CAS  Google Scholar 

  • Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, Tannenbaum SR (1994) Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369:154–156

    Article  PubMed  CAS  Google Scholar 

  • Wikman H, Thiel S, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H, Risch A (2001) Relevance of N-acetyltransferases 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 11:157–168

    Article  PubMed  CAS  Google Scholar 

  • Wild CP (2005) Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 14:1847–1850

    Article  PubMed  CAS  Google Scholar 

  • Zochbauer-Muller S, Pirker R, Huber H (1999) Treatment of small cell lung cancer patients. Ann Oncol 10[Suppl 6]:83–91

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Toxicology and Cancer Risk Factors, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Helmut Bartsch (Prof.), Heike Dally, Odilia Popanda PhD, Angela Risch PhD & Peter Schmezer PhD

Authors
  1. Helmut Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heike Dally
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Odilia Popanda PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Risch PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Schmezer PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tumor-Zentrum ZeTuP St. Gallen/Chur (Tumordiagnostik, Behandlung + Prävention), Rorschacherstr. 150, CH-9006, St. Gallen, Schweiz

    Hans-Jörg Senn  & Ursula Kapp  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bartsch, H., Dally, H., Popanda, O., Risch, A., Schmezer, P. (2007). Genetic Risk Profiles for Cancer Susceptibility and Therapy Response. In: Senn, HJ., Kapp, U. (eds) Cancer Prevention. Recent Results in Cancer Research, vol 174. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-37696-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-37696-5_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-37695-8

  • Online ISBN: 978-3-540-37696-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation